How M.D. was paid
$13.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Michael Davidson, M.D.Chief Executive Officer | $646,152 | $3,571,146 | $8,931,566 | $474,922 | $18,068 | $13,641,854 |
| Ian SomaiyaChief Financial Officer | $486,720 | $986,480 | $2,941,030 | $269,673 | $14,000 | $4,697,903 |
| Louise KooijChief Accounting Officer | $452,217 | $470,795 | $1,069,465 | $220,455 | $22,747 | $2,235,679 |
| John Kastelein, M.D., Ph.D. FESCChief Scientific Officer | $537,866 | $1,330,324 | $2,673,664 | $270,277 | — | $4,812,131 |
| Douglas KlingChief Operating Officer | $519,967 | $1,305,037 | $3,342,080 | $256,084 | $14,000 | $5,437,168 |
What changed and why
- 13,641,854 was Dr. Davidson’s 2025 total compensation, compared with 6,469,297 in 2024.
- 200%200% was the maximum annual cash incentive payout, measured as a percentage of target.
- 60%60% of base salary was Dr. Davidson’s fiscal 2026 target annual performance bonus.
- March 26, 2025 Earnout RSUs granted to NEOs vested fully on the grant date.
- No defined-benefit pension or post-retirement health coverage was provided.
- 98%Over 98% of votes cast supported 2025 say-on-pay at the prior annual meeting.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.